ProPerty, PLAnt And equIPment Continued Land and machinery and Fixtures and Projects under buildings vehicles equipment equipment construction total $000 $000 $000 $000 $000 $000 Charge for the year 5,321 1,813 17,102 4,855 29,091 Acquisition of subsidiaries 2,321 201 3,128 619 6,269 disposals and transfers 9 410 1,975 111 2,505 translation adjustment 823 117 1,970 495 3,405 Balance at 31 December 2010 34,550 7,312 111,551 26,912 180,325 Carrying amount At 31 December 2010 142,188 6,234 106,864 17,051 45,126 317,463 Carrying amount At 31 December 2009 127,065 5,233 94,911 16,512 39,650 283,371 The net book value of the Groups machinery and equipment includes an amount of USD 11,862,000 2009: USD 12,743,000 in respect of assets held under finance lease.
As at 31 December 2010 the Group had pledged property, plant and equipment having a carrying value of USD 80,557,000 2009: USD79,557,000 as collateral for various long-term loans.
This amount includes both specific items around the Group and the net property, plant andequipment of the Groups businesses in Portugal, Saudi Arabia, US and Tunisia.
In 1994, the Portuguese Government granted Hikma Farmaceutica an amount of Euro 1,600,000 to build the Companys factory in accordancewith the SINPEDIP programme.
In 2008, the German Government provided Thymoorgan Pharmazie GmbH a grant of Euro 560,000 being a contribution towards the acquisition of two freeze dryers and additional equipment.
The carrying value of the grants as of 31 December 2010 were USD nil 2009: USD 40,000 for Hikma Farmaceutica and USD 336,000 2009: 454,000 for Thymoorgan Pharmazie GmbH.
During the year 2010, the Group entered into contractual commitments for the acquisition of property, plant and equipment amounting to USD 373,000 2009: USD 776,000.
The amount of borrowing costs that have been capitalised in the year within the projects under construction is USD 1,620,000 2009: USD422,000.
The average capitalisation rate used ranges between 2.9%10.6%.
Interest In JoInt venture In 2009, the investment in joint venture represented the Group joint venture in Al Dar Al Arabia Pharmaceutical Manufacturing Company.
TheGroup share of the joint venture as at 31 December 2009 was USD 5,451,000.
During 2010 the Group increased its equity interest in Al Dar Al Arabia Pharmaceutical Manufacturing Company to 100% and therefore, theresults of this company were consolidated within Hikma Group consolidated financial statements and are no longer considered to be as a joint venture.
